LFG
JBIO

Larson Financial Group’s Jade Biosciences JBIO Stock Holding History

Larson Financial Group’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.31K Hold
104
– – ﹤0.01% 3065
2026
Q1 		$1.46K Buy
104
+81
+352% +$1.17K ﹤0.01% 3057
2025
Q4 		$355 Buy
+23
New +$270 ﹤0.01% 3186

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Larson Financial Group's JBIO Position: Q2 2026 in Review

Larson Financial Group held its Jade Biosciences (JBIO) position steady in Q2 2026 at 104 shares worth $2.31K. The position accounts for ﹤0.01% of the portfolio, ranked #3065.

Larson Financial Group first reported a position in JBIO in Q4 2025 and has held it in 3 quarters since. 153 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Larson Financial Group held 104 shares of Jade Biosciences worth $2.31K as of Q2 2026.
  • Larson Financial Group left its Jade Biosciences share count unchanged in Q2 2026.
  • Jade Biosciences made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3065 holding.
  • Larson Financial Group first reported a position in Jade Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 153 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.